Wockhardt shuts US manufacturing plant

The company expects the US plant shutdown and transfer of products from inhouse to third-party contract manufacturers to help save $12 million annually, while maintaining the sales run rate with a 40% gross margin. A few products with high margin will be manufactured by third parties, the company said in an investor presentation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ySQkmH5
via IFTTT